Some information on this page may be available only to Healthcare Professionals. Please

About

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. To learn more about Novartis in Singapore, visit https://www.novartis.com.sg

Website: https://www.novartis.com.sg/

Facebook: https://www.facebook.com/novartis

Twitter: https://twitter.com/novartis

Youtube: https://www.youtube.com/channel/UCrOUkNI1eCMumFJ1PK6PaYw

Instagram: http://instagram.com/novartis

LinkedIn: https://www.linkedin.com/company/novartis-sg/

Media

Videos

Branches

1

Novartis

20 Pasir Panjang Road #10-25/28, Mapletree Business City (West Tower), Singapore 117439

Key Trials

2 trials shown

Novartis

Novartis

Official trial

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

7 September 2020

The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

Trial number: NCT04240704 Study type: chemotherapy, targeted Trial phase: 1 Overall status: Recruiting
Novartis

Novartis

Official trial

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

26 May 2017

The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.

Trial number: NCT03114319 Study type: targeted, biomarker Trial phase: 1 Overall status: Recruiting